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Abstract 
Pharmacological manipulation of survivin seems to be an attractive option in the treatment of 
several conditions of pathological remodeling. In the present study, we characterized in vivo 
effects of a pharmacological inhibitor of survivin, terameprocol (TMP), in the monocrotaline 
(MCT) model of PAH. Adult male Wistar rats received a subcutaneous injection of MCT (60 
mg/Kg) or equal volume of vehicle. Rats injected with MCT were treated with TMP (166 
mg/Kg, ip; MCT-TMP, n=15) or vehicle (MCT-V, n=15) on days 7, 12 and 17 after injection 
and compared with SHAM animals, treated with either TMP (SHAM-TMP, n=10) or vehicle 
(SHAM-V, n=10).  TMP treatment reduced RV hypertrophy and pulmonary arterial wall 
thickness, decreased RV peak systolic pressure, dP/dtmax and dP/dtmin and normalized cardiac 
output, thereby reversing the pathological phenotype induced by MCT injection. Our findings 
suggest an important pathological role of survivin in PAH development. Furthermore, 
terameprocol could be an effective and highly selective therapeutic strategy for PAH by 
reversing cardiac and pulmonary remodeling and improving hemodynamic features. 
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Introduction 
The vascular obstruction seen in Pulmonary arterial hypertension (PAH) results from a 
combination of increased pulmonary vasoconstriction, abnormal vascular remodeling and in situ 
thrombosis of pulmonary vessels, affecting all vessel layers [40]. Obstructive vascular 
remodeling is characterized by increased cellular proliferation and resistance to apoptosis in 
both intima and media and is now thought to be the major cause of increased pulmonary 
vascular resistance in PAH. [3, 40].  
Survivin is a multifunctional protein, involved in the control of mitosis, the regulation of 
apoptosis and the cellular stress response, globally promoting proliferation and apoptosis-
resistance [2, 11, 44]  . It is highly expressed during embryonic and fetal development and in 
most liquid and solid tumours [23, 25, 33, 45], but it is almost undetectable in most 
differentiated tissues in the absence of stress conditions. Moreover, survivin is an unfavourable 
prognostic marker in several malignancies, correlated with decreased overall survival [33]. 
Survivin has also been studied in other conditions of pathological remodeling, including in 
vascular injury after angioplasty or vein bypass graft surgery [13, 17]. In the pulmonary 
vasculature, survivin was found to be expressed in the PAs of patients with and several animal 
models of PAH [14, 28, 30, 46, 51]. Additionally, gene therapy targeting survivin reversed 
established MCT-induced PAH [30]. Pharmacological manipulation of survivin seems an 
attractive option. Terameprocol (tetra-O-methyl nordihydoguaiaretic acid, M4N or EM-1421) is 
an inhibitor of surivivin gene expression by binding the transcription factor Sp1 [12, 16, 20]. Its 
efficacy has been established both in vitro and in vivo, displaying increased tumor cell apoptosis 
and growth arrest with decreased tumor growth rates as well as a direct tumoricidal activity [12, 
16, 20, 36, 43]. So far, no relevant systemic toxicity has been reported with terameprocol 
treatment.  
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In the present study, we aim to characterize survivin role in the pathophysiology of PAH 
induced by MCT by abrogation of survivin expression with its pharmacological inhibitor, 
terameprocol.  
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Material and Methods 
Chemical and Drugs 
MCT and dimethylsulfoxide (DMSO) were from Sigma (Barcelona, Spain). TMP was from 
Cayman Chemical (Michigan, USA). TMP was dissolved in DMSO.  
Experimental Design 
Animal experiments were performed according to the Portuguese law for animal welfare and 
conform to the National Institutes of Health Guide for the Care and Use of Laboratory Animals 
(NIH Pub. No. 85-23, Revised 2011). Adult male Wistar Han rats (Charles River Laboratories, 
Barcelona, Spain) weighing 180-200 g were housed in groups of 5 animals/cage, in a controlled 
environment under a 12:12-h light-dark cycle at a room temperature of 22ºC, with free supply of 
food and water. Rats randomly received a subcutaneous injection of MCT (60 mg/kg) (MCT 
groups, n=30) or an equal volume of vehicle (1 mL/kg of 0.9% NaCl) (SHAM groups, n=20). 
At day seven after MCT or vehicle injection, DMSO (1mL/Kg, n=25) or TMP (166 mg/Kg, 
n=25) were administered intraperitoneally and at every five days until hemodynamic evaluation 
(21 days after MCT or vehicle injection). The time point for DMSO or TMP administration was 
based on a preliminary study, thus coinciding with the first evidence of survivin expression in 
pulmonary hypertensive animals. Four experimental groups were thus created: i) SHAM 
injected with DMSO (n=10); ii) SHAM injected with TMP (n=10); iii) MCT injected with 
DMSO (n=15); iv) MCT injected with TMP (n=15).  
Hemodynamic Analysis and Tissue Sampling 
Animals were anesthetized by inhalation of mixture of sevoflurane (4%) and oxygen, intubated 
for mechanical ventilation (Dual Mode, Kent Scientific, Connecticut, USA) and placed over a 
heating pad (body temperature was maintained at 37°C). Under binocular surgical microscopy 
(Wild M651.MS-D, Leica; Herbrugg, Switzerlad), the right jugular vein was cannulated for 
fluid administration (prewarmed 0.9% NaCl solution) to compensate for perioperative losses. 
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The heart was exposed by a median sternotomy and the pericardium was widely opened. Bi-
ventricular hemodynamic function was measured with pressure-volume (PV) catheters (PVR-
1045 for RV and PVR-1035 for LV, Millar instruments, Houston, USA). Data was continually 
acquired (MPVS 300, Millar Instruments, Houston, USA) and digitally recorded at 1000Hz 
(ML880 PowerLab 16/30, Millar TM instruments, Houston, USA). After complete 
instrumentation, the animal preparation was allowed to stabilize for 15 min. Hemodynamic 
recording was made under basal conditions and under vena cava, ascending aorta or pulmonary 
artery occlusion with respiration suspended at end-expiration. Heart rate (HR), RV and LV peak 
systolic pressure (Pmax), end-diastolic pressure (EDP), peak rate for pressure rise (dP/dtmax), peak 
rate of pressure decline (dP/dtmin), constant time of isovolumetric pressure decline (Tau), 
ejection fraction (EF), cardiac output (CO) and maximal elastance (Ea) were obtained and 
analysed using PVAN 3.5 and LabChart 7.0 (Millar Instruments, Houston, USA). After 
complete hemodynamic assessment, animals were euthanized by exsanguination under 
anesthesia. The heart (H), lungs (L) and right gastrocnemius muscle were excised and weighted. 
The right tibia was also excised and its length was measured with a millimetric ruler. Under 
binocular magnification (x3.5, Wild M651.MS-D, Leica; Herbrugg, Switzerlad), the RV free 
wall was dissected from the left ventricle + septum (S) and weighted separately. Heart, lungs, 
RV and LV+S weights were normalized to body weight (BW) and gastrocnemius weight was 
normalized to tibial length. Samples from heart and lung were fixed and included in paraffin for 
light microscopy, or frozen with liquid nitrogen for molecular studies. 
Morphometric Analysis 
Samples of RV, LV (midway between the apex and base) and lung were fixed in 4% (v/v) 
buffered paraformaldehyde and included in paraffin blocks. Serial sections (4 μm of thickness) 
of paraffin blocks were cut and stained for haematoxylin-eosin. Studied samples were observed 
at light microscopy (Dialux 20, Leitz, Wetzlar, Germany), photographed with a digital camera 
(XC30, Olympus, California, USA) and measured with a digital image analyzer (cell^B life 
science basic imaging software, Olympus, California, USA). Five images of random 
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microscopic fields (magnification of x400) were obtained from each section to compensate for 
variations within sections. Only round to ovoid muscle fibers with a nuclear profile were 
counted to measure the cardiomyocytes surface area (CSA) with 50 cardiomyocytes analyzed 
per animal. On pulmonary specimens, external diameter and medial wall thickness in muscular 
arteries (20-25 arteries/animal) were analyzed. 
Statistical Analysis 
Statistical analysis was performed using Graph Pad Prism software (version 5.0, Graph Pad 
software, California, USA). All data are presented as mean ± SEM and were compared using 
Two Way ANOVA. When treatments were significantly different, Students-Newman Keuls 
post-hoc test was selected to perform pairwise multiple comparisons. Results were considered 
significantly different when p<0.05. 
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Results 
Morphometric Analysis 
The effects of TMP on the morphometric progression of MCT-induced PAH are summarized in 
Table 1. MCT-treated animals exhibited lower body weight when compared with the 
Sham+Vehicle group, that was not altered by treatment with TMP. 
In the lung, MCT increased L/BW ratio, which was attenuated by TMP administration (Figure 
1B). Pulmonary remodeling was also evident at the histological level, with increased medial 
hypertrophy of small caliber pulmonary arteries in MCT+Vehicle treated animals (Figures 1A 
and 1C). TMP targeted the abnormal pulmonary remodeling, reducing medial hypertrophy in 
the MCT-treated group (Figures 1A and 1C). No significant differences were noted in the Sham 
groups. 
Regarding cardiac remodeling, MCT treatment induced cardiac hypertrophy, as evidenced by 
increased heart weight (HW) to BW ratio in the MCT+vehicle group. Cardiac hypertrophy was 
most likely due to RV hypertrophy, since RV/LV+S weight and RV/BW ratios were also found 
to be increased (Figure 2A). Treatment with TMP abrogated MCT-induced cardiac hypertrophy, 
resulting in normalization of HW/BW, RV/BW and RV/LV+S weight ratios (Figure 2A). 
These results were further confirmed by histological analysis of the RV (Figure 2B). 
Cardiomyocyte cross-sectional area (CSA) was increased in MCT+vehicle animals, supporting 
the macroscopic finding of RV hypertrophy. Likewise, treatment with TMP resulted in a 
significant reduction of cardiomyocyte CSA, with no statistically significant difference between 
MCT+TMP treated animals and controls.  
 
Hemodynamic evaluation 
Table 2. summarizes the results from the bi-ventricular hemodynamic evaluation. 
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RV function was markedly impaired in MCT+vehicle treated animals. In this group, RV systolic 
dysfunction in connection with increased RV afterload was suggested by the combination of 
increased dP/dtmax, dP/dtmin, Ea and Pmax and decreased EF and CO (Figures 3A and 3B). TMP 
administration normalized these parameters, proving to be beneficial in the regularization of RV 
strain and RV systolic impairment (Figures 3A and 3B). Diastolic function was also 
compromised, as evidenced by increased EDP and Tau time constant in the MCT+vehicle 
group, which was also ameliorated by TMP treatment. No significant changes were noted in the 
hemodynamic evaluation of the LV. 
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Discussion 
In the present study, we have demonstrated that inhibiting survivin throughout the early stages 
of MCT-induced PAH prevents the complete development of the pulmonary and cardiac 
remodeling as well as the RV dysfunction that characterizes the disease. Our findings thus 
indicate that survivin upregulation is an essential maladaptive phenomenon that contributes to 
the full establishment of PAH pathology.  
Traditionally, PAH was considered a disease of excess vasoconstriction [3] but the observation 
that more than 85% of patients are unresponsive to current available vasodilator therapies at the 
time of diagnosis has challenged this view [47]. Abnormal vascular remodeling affecting all 
vessel layers, on the other hand, has emerged as the major contributor to disease initiation and 
progression [47]. Several mechanisms have been implicated in the switch from a quiescent state 
to a proliferative, apoptosis-resistant cellular phenotype, including: loss-of-function mutations 
in bone morphogenetic protein receptor 2 (BMPR2) [21]; upregulation of growth factors,   [22, 
37, 41, 42] and dysregulation of mediators of apoptosis, such as bcl-2 or survivin [15, 30, 39]. 
Several studies are currently trying to identify which of these mechanisms are amenable to 
therapeutic modulation, with encouraging results [7, 18, 24, 35, 41].   
Survivin presents unique advantages over these candidate modulators of PAH; as the paradigm 
of a “nodal protein” survivin is involved in multiple cell signalling circuits, thereby representing 
a central player in a non-redundant network for the maintenance of disordered proliferation and 
apoptosis [1]. This central role of survivin is highlighted by its upregulation by several growth 
factors [14, 17, 28, 49], vasoactive molecules [14, 19, 28, 34] and inflammatory cytokines [14, 
46], providing further support for survivin as a downstream effector in the signalling cascades 
of various neurohormones and other modulators of PA cell proliferation and apoptosis. 
These “survivin networks” may also provide a new insight into RV dysfunction in PAH. 
Bogaard et al. [6] brought into question the commonly held concept that RV failure is due 
strictly to the increased RV afterload by comparing a RV pressure overload model with an 
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established model of angioproliferative PAH and consistently demonstrating features of right 
heart failure in the latter but not the former model. Two important results from a previous 
unpublished study from our group also support this notion: 1) RV survivin expression preceded 
the hemodynamic manifestations of PAH, including the increase in PA systolic pressure, by 7 
days, coinciding with the onset of cardiomyocyte hypertrophy determined by histological 
analysis; 2) LV survivin expression was also increased when compared to control animals. We 
thus hypothesize that the release of neurohormones and paracrine factors from the injured and 
remodeling PA is the initiating mechanism of RV failure in PAH, by inducing RV 
cardiomyocyte survivin upregulation and the consequent switch to a hypertrophic, apoptosis-
resistant cellular phenotype. The concomitant increase in RV afterload would aggravate RV 
dysfunction eventually leading to RV failure [5, 10]. In accordance, Levkau et al. [27] observed 
significant load-dependence of survivin expression in the setting of left heart failure and showed 
that cardiac-specific deletion of survivin resulted in left heart failure and premature cardiac 
death. Survivin also appears to be protective after acute myocardial infarction, in doxorubicin-
induced cardiomyopathy and in the failing heart of aged spontaneously hypertensive rats, 
despite being selectively expressed in diseased animals [26, 29, 32] . Thus, it seems that 
survivin upregulation is an expected and adaptive response to injury, contributing to injury 
repair. Continued injury and cellular stress as well as its related signalizing molecules lead to 
maintained survivin overexpression and its deleterious, maladaptive effects, such as the 
pathological PA and RV remodeling in PAH. 
Survivin antagonists might present an unique therapeutic opportunity in PAH: they may 
function not as single protein inhibitors but, in fact, as broader pathway inhibitors suitable for 
disabling multiple downstream signalling cascades within PA cells [1] and they may target not 
only the pathological remodeling of PAs but also act directly on the RV to abrogate the 
hypertrophic profile of RV cardiomyocytes. In the present study, the pharmacological inhibitor 
of survivin terameprocol was administered throughout the progression of MCT-induced PAH 
and we are thus unable to conclude on its therapeutic potential other than as a preventive 
12 
 
strategy. Unfortunately, most patients present with advanced disease, limiting the direct clinical 
implications of this study. Nevertheless, our current results merit additional investigation into 
the possible use of terameprocol in established PAH. 
Further studies are also warranted to better delineate the survivin axis in PAH, including 
identification of the neurohumoral and paracrine mediators of survivin expression with various 
candidate molecules mentioned above. Of special note, mitochondrial-metabolic abnormalities 
are emerging as an unifying mechanism for the pathological remodeling of PAH, in accordance 
with previous observations in cancer [4, 9, 50]. In both PAH and cancer, mitochondrial 
hyperpolarization and disordered mitochondrial metabolism and redox signalling lead to a 
pseudohypoxic redox state characterized by normoxic decreases in reactive oxygen species, a 
shift from oxidative to glycolytic metabolism, HIF-1α activation and decreased Kv1.5 K+ 
channel expression [4, 8, 38]. Therapies targeting these mitochondrial abnormalities have 
provided good outcomes in a pre-clinical level [29, 32]. Survivin function in mitochondrial 
biology suggests a likely interaction with this mechanism. 
Lastly, it is also important to note that in spite of being a classic and thoroughly studied model 
of PAH, MCT-induced PAH does not fully mimic human pathology [4, 31]. Limitations of 
MCT models include lack of neointimal thickening and plexiform lesions and a rapid time 
course for disease development [48]. Newer models have been developed, e.g. the SU5416 and 
hypoxia, IL-6 overexpression or the fawn-hooded rat, some with better correlation with human 
disease. Notwithstanding these advances, no preclinical model completely recapitulates human 
PAH at present [48]. 
In conclusion, we have shown that pharmacological suppression of the survivin pathway 
attenuated the pathological and hemodynamic phenotype of MCT-induced PAH thereby 
establishing survivin’s crucial role in the pathophysiology of PAH. Furthermore, we have 
unraveled a potential, highly selective therapeutic strategy in the treatment of PAH, capable of 
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effectively halting progression of the disease and providing an opportunity to alter its still 
irrevocable natural history.  
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Figure captions 
Figure 1: Effect of terameprocol in pulmonary remodeling. Terameprocol attenuated the 
characteristic pulmonary remodeling of monocrotaline-treated animals evaluated by the 
histological appearance of small pulmonary arteries stained with hematoxylin and eosin (A), 
lung weight/body weight ratio (L/BW) (B) and percentage of medial hypertrophy of pulmonary 
arteries (C). Sham: Sham group, MCT: Monocrotaline group, TMP: Terameprocol. Data are 
mean±SEM. 
α
p < 0.05 vs. Sham+V, 
β
p < 0.05 vs. Sham+TMP and 
γ
p < 0.05 vs. MCT+V. 
Figure 2: Effect of terameprocol in right ventricular remodeling. Terameprocol reversed 
right ventricular hypertrophy in the monocrotaline groups evaluated by right ventricle/ body 
weight ratio (RV/BW) (A) and cardiomyocyte cross sectional area (CSA) (B). Sham: Sham 
group, MCT: Monocrotaline group, TMP: Terameprocol. Data are mean±SEM. 
α
p < 0.05 vs. 
Sham+TMP, 
β
p < 0.05 vs. MCT+V. 
Figure 3: Effect of terameprocol in right ventricular hemodynamics. Terameprocol 
normalized RV maximal systolic pressure (A) and RV cardiac output (B). Pmax: maximal 
systolic pressure. CO: cardiac output. Data are mean±SEM. 
α
p < 0.05 vs. Sham+V, 
β
p < 0.05 vs. 
Sham+TMP and 
γ
p < 0.05 vs. MCT+V. 
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Tables 
Table 1: Effect of terameprocol in morphometric parameters. 
 Sham MCT 
 Vehicle TMP Vehicle TMP 
Body weight (g) 300.1 ± 8.2  268.6 ± 11.4  258.6 ± 5.6
α  249.7 ± 8.0α  
HW/BW (g/kg) 3.013 ± 0.103  2.734 ± 0.096  3.634 ± 0.317
α,β  3.068 ± 0.176γ  
RV/(LV+S) (g/g)  0.3043 ± 0.0109  0.3401 ± 0.0299  0.4589 ± 0.0362
α,β  0.3685 ± 0.0189γ  
(LV+S) /BW (g/Kg)  1.856 ± 0.052  1.771 ± 0.063  2.035 ± 0.081  1.837 ± 0.044  
G/Tib (g/cm)  0.5200 ± 0.0147  0.4857 ± 0.0092  0.4951 ± 0.0138  0.4290 ± 0.0177  
 
HW/BW: heart weight/body weight; RV/(LV+S): right ventricle/(left ventricle+septum); 
(LV+S)/BW: (left ventricle+septum)/body weight; G/Tib: gastrocnemius/tibia. Sham: Sham 
group; MCT: Monocrotaline group; TMP: Terameprocol. Data are mean±SEM.
 α
p < 0.05 vs. 
Sham+Vehicle; 
β
p < 0.05 vs. Sham+TMP; 
γ
p < 0.05 vs. MCT+Vehicle. 
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Table 2: Effect of terameprocol in hemodynamic parameters. 
 Sham MCT 
 Vehicle TMP Vehicle TMP 
Heart rate (bpm)  380.5 ± 8.402  376.5 ± 8.425  365.4 ± 5.608  386.1 ± 7.373  
RV Function 
dP/dt max (mmHg/sec)  1500 ± 26.55  1627 ± 65.47  3450 ± 468.6
α β  2107 ± 83.22γ  
dP/dt min (mmHg/sec)  -1485 ± 151.4  -1325 ± 18.62  -2903 ± 165.4 
α β  -1763 ± 27.86 β γ  
EF (%)  65.42 ± 5.536  70.04 ± 3.858  29.41 ± 4.383 
α β  70.56 ± 4.902 γ  
EDP (mmHg)  2.951 ± 0.1836  3.561 ± 0.4696  6.424 ± 1.137 
α β  3.165 ± 0.6209 γ  
Ea (mmHg/μL)  0.1528 ± 0.0115  0.1468 ± 0.0079  0.7701 ± 0.1588 
α β  0.2661 ± 0.0372 γ  
Tau (ms)  10.84 ± 0.7640  10.43 ± 0.7636  15.96 ± 0.3210 
α β  9.229 ± 0.7491 γ  
LV Function 
Pmax (mmHg)  84.89 ± 5.706  94.14 ± 1.525  97.17 ± 4.977  94.66 ± 3.743  
dP/dt max (mmHg/sec)  5582 ± 460.5  6517 ± 297.9  5724 ± 217.8  5518 ± 321.0  
dP/dt min (mmHg/sec)  -5180 ± 888.4  -6785 ± 430.0  -5242 ± 458.3  -6434 ± 380.8  
EF (%)  73.82 ± 3.931  72.89 ± 4.410  71.47 ± 2.945  68.72 ± 3.969  
EDP (mmHg)  5.427 ± 1.538  4.376 ± 1.272  4.531 ± 0.7069  6.576 ± 1.885  
Ea (mmHg/μL)  0.4007 ± 0.076  0.4911 ± 0.0645  0.7408 ± 0.1039  0.7330 ± 0.1712  
Tau (ms)  8.609 ± 0.3356  9.136 ± 0.8681  9.015 ± 0.5702  9.754 ± 0.6173  
 
Sham: Sham group, MCT: Monocrotaline group. TMP: Terameprocol; Pmax: maximum pressure; 
dP/dtmax: peak rate of pressure rise; dP/dtmin: peak rate of pressure fall; EF: Ejection fraction; 
EDP: end-diastolic pressure; Ea: arterial elastance; Tau: time constant of ventricular decay. Data 
are mean±SEM.
 α
p < 0.05 vs. Sham+Vehicle; 
β
p < 0.05 vs. Sham+TMP; 
γ
p < 0.05 vs. 
MCT+Vehicle. 
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